Boston begins German trials on paclitaxel-coated stents
This article was originally published in Clinica
Clinical trials of Boston Scientific's paclitaxel-coated coronary stents are to begin in Germany. The dose-escalating study, which aims to evaluate the safety and feasibility of the device for reducing restenosis, is the first human trial of the company's drug-coated stents for coronary indications. The trial is due to begin in the second quarter of this year.